OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← All Supported Cancers

Colorectal Cancer (CRC) — Options & Clinical Trial Reference

Source-cited reference covering MMR/MSI status, KRAS/NRAS, BRAF V600E, HER2 amplification, sidedness, surgical/systemic settings, and recruiting trials.

Module v2.0.0-nofda-prototype · Curated SHA-256: 80ed92210198ee05 · Trial Snapshot: 2026-10-23

Key Biomarkers & Decision Factors:
biomarkerspending_status_values

Unranked Guideline & FDA-Label Option Categories (34 total)

Option / PathwayCategoryPrimary Sources
Stage 0/I colon local treatment review
Confirm endoscopic/pathological features and definitive local management.
care_pathwayNCI-COLON
Stage II colon observation discussion
Routine adjuvant chemotherapy is not recommended in the absence of a high-risk subgroup.
care_pathwayNCI-COLON, pdq_colon
Stage II colon adjuvant risk/benefit review
Discuss adjuvant treatment; T4 and other high-risk findings have different recommendation strength.
conventional_therapyNCI-COLON, pdq_colon, FDA-DPD, FDA-XELODA-2025, xeloda
Stage II dMMR colon specialist review
Do not routinely offer adjuvant chemotherapy solely because stage II disease is present; high-risk cases require individual review.
care_pathwayNCI-COLON, pdq_colon
Stage III colon FOLFOX / CAPOX review
Discuss oxaliplatin plus fluoropyrimidine adjuvant therapy following resection.
conventional_therapyFDA-DPD, FDA-XELODA-2025, LABEL-OXALIPLATIN, NCI-COLON, pdq_colon, pm_29590544, pm_29611518, oxaliplatin
Stage 0/I rectal local treatment review
Determine whether local excision or oncologic resection is appropriate.
care_pathwayNCI-RECTAL
Locally advanced rectal total neoadjuvant therapy review
Discuss total neoadjuvant therapy (induction vs consolidation chemotherapy; long-course CRT vs short-course RT) before restaging and local management.
conventional_therapyNCI-RECTAL, pdq_rectal, pm_35483010, pm_37883738, pm_33301740, pm_33862000, FDA-DPD, FDA-XELODA-2025
Lower-risk locally advanced rectal selective-radiation discussion
In cT2N+, cT3N-, or cT3N+ sphincter-sparing candidates, neoadjuvant FOLFOX with selective pelvic chemoradiotherapy (reserved for <20% primary tumor decrease or FOLFOX intolerance) was noninferior to preoperative CRT for 5-year DFS (80.8% vs 78.6%, HR 0.92).
care_pathwayNCI-RECTAL, pdq_rectal, pm_37272534, FDA-DPD, LABEL-OXALIPLATIN
Dostarlimab (JEMPERLI) for MSI-H or dMMR stage II/III locally advanced rectal cancer
Discuss single-agent dostarlimab (JEMPERLI §1.2) with the rectal multidisciplinary team.
biomarker_selected_therapyLABEL-JEMPERLI-2026-10, pdq_rectal
Rectal complete-response organ-preservation discussion
Watch-and-wait organ preservation discussion for clinical complete response or near-complete response after TNT under structured endoscopic, DRE, and pelvic MRI surveillance, with salvage TME for local regrowth (5-yr DFS after TME at restaging vs TME at regrowth 64% vs 64% in OPRA).
care_pathwayNCI-RECTAL, pdq_rectal, pm_35483010, pm_37883738
Potentially curable metastatic local-treatment review
Multidisciplinary hepatobiliary/thoracic surgical and local-therapy review at baseline and restaging (~2-month intervals during conversion systemic therapy to limit chemotherapy-associated steatohepatitis/sinusoidal injury).
care_pathwayNCI-COLON, pdq_colon, pdq_rectal
Pembrolizumab first-line review
Selected molecular and treatment-setting conditions match the approval context.
biomarker_selected_therapyFDA-PD1
Nivolumab + ipilimumab review
Selected MSI-H/dMMR metastatic conditions match the approval context; trial evidence is immunotherapy-naive.
biomarker_selected_therapyFDA-NIVO-IPI, opdivo
FOLFOX / FOLFIRI + anti-VEGF review
Discuss a chemotherapy doublet strategy with anti-VEGF treatment where appropriate.
conventional_therapyNCI-COLON, pdq_colon, avastin, FDA-DPD, FDA-XELODA-2025, LABEL-BEVACIZUMAB, LABEL-IRINOTECAN, LABEL-OXALIPLATIN
Left-sided RAS/BRAF-wild-type doublet + anti-EGFR review
The first-line anti-EGFR discussion is restricted to reviewed RAS wild type and left-sided primary. This preferred anti-EGFR doublet pathway requires both RAS and BRAF wild type; this does not exclude cetuximab within BRAF-targeted combinations.
biomarker_selected_therapyNCI-COLON, pdq_colon, erbitux, vectibix, pm_35666229, FDA-DPD, FDA-XELODA-2025, LABEL-IRINOTECAN

View all 34 Colorectal Cancer (CRC) reference options →

Recruiting Clinical Trials (507 curated)

NCT IDStudy TitlePhase
NCT01174121Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerPHASE2
NCT01365169Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"NA
NCT02000089The Cancer of the Pancreas Screening-5 CAPS5)StudyPHASE3
NCT02172651Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver MetastasesEARLY_PHASE1
NCT02448173A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon CancerPHASE3
NCT02584244Feasibility of the LUM Imaging System for Detection of Gastrointestinal CancersPHASE1|PHASE2
NCT02600949Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerPHASE1
NCT03051464Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer SurgeryPHASE2|PHASE3
NCT03093116A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsPHASE1|PHASE2
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsPHASE2
NCT03190941Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsPHASE1|PHASE2
NCT03516708Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal CancerPHASE1|PHASE2

View all 507 Colorectal Cancer (CRC) clinical trials →